PON1, A New Biomarker of Cardiovascular Disease, Is Low in Patients with Systemic Vasculitis
Section snippets
Patients
Thirty-three patients with active SV (ASV) (10 men, 23 women; mean ± SD age: 60.9 ± 15.7 years old) were included in the study. Exclusion criteria were the following: history of diabetes mellitus or hyperlipidemia; end-stage renal disease (ESRD; creatinine clearance, <30 mL/min), and/or statin or fibrate therapy. Twenty-one patients had small-vessel SV (Wegener’s granulomatosis [WG], n = 7, microscopic polyangiitis [MPA], n = 7, Churg–Strauss syndrome [CSS], n = 1, Henoch–Schönlein purpura
Results
The main demographic and biological characteristics of the tested populations are reported in Table 1. Plasma CRP levels were significantly higher in ASV patients than those in RSV or HS. Plasma HS-CRP of RSV patients was determined when CRP was undetectable (n = 22); they tended to be higher in patients in RSV than in HS. Creatininemia was significantly higher in RSV patients than those with ASV.
PON1 basal activity levels differed significantly among our 3 groups (ANOVA, P = 0.008) (Table 1).
Discussion
The results of our study show that aCL autoAb titers were higher in ASV patients than HS and that ox-LDL, MDA-LDL autoAb titers were higher in RSV than ASV patients or HS. Several authors reported that high autoAb titers to ox-LDL titers were associated with atherosclerosis, although some findings remain controversial (28, 29). Our results confirm the observations made by Swets and coworkers on 25 ASV patients (12), but it must be kept in mind that diabetes mellitus and ESRD have been reported
References (47)
Update on systemic necrotizing vasculitis
Mayo Clin Proc
(1989)- et al.
Cardiac complications of Wegener’s granulomatosis: a case report of complete heart block and review of the literature
Semin Arthritis Rheum
(1980) - et al.
Association of paraoxonase-1 activity and concentration with angiographic severity and extent of coronary artery disease
J Am Coll Cardiol
(2006) A simplification of the protein assay method of Lowry et al. which is more generally applicable
Annal Biochem
(1977)- et al.
Detection of autoantibodies against oxidized low-density lipoproteins and of IgG-bound low-density lipoproteins in patients with coronary artery disease
Clin Chim Acta
(1995) - et al.
Autoantibody against oxidised LDL and progression of carotid atherosclerosis
Lancet
(1992) - et al.
The pravastatin inflammation CRP evaluation (PRINCE): rationale and design
Am Heart J
(2001) - et al.
Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia: relations with baseline lipid profiles
Atherosclerosis
(2003) - et al.
Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase
Atherosclerosis
(1993) - et al.
Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials
Lancet
(2003)
Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial
Lancet
The vasculitic syndromes
Adv Intern Med
Cardiovascular disease incidence and risks factors in ANCA-associated primary systemic vasculitis (AASV)
Arthritis Rheum
Thrombo-embolic and vascular complications in vasculitis syndromes
Eur Heart J
Increased mortality due to cardiovascular disease in patients with giant cell arteritis in northern Sweden
J Rheumatol
Takayasu’s arteritis
Ann Intern Med
Immune-complex-mediated vasculitis increases coronary artery lipid accumulation in autoimmune-prone MRL mice
Arterioscler Thromb
Atherosclerosis—an inflammatory disease
N Engl J Med
Low-density lipoprotein undergoes oxidative modification in vivo
Proc Natl Acad Sci USA
Circulating intercellular adhesion molecules-1 and autoantibodies including anti-endothelial cell, anti-cardiolipin, and anti-neutrophil cytoplasma antibodies in patients with vasculitis
Clin Rheumatol
Patients with systemic vasculitis have increased levels of autoantibodies against oxidized LDL
Clin Exp Immunol
The paraoxonase gene family and coronary heart disease
Curr Opin Lipidol
Pharmacogenomic considerations of the paraoxonase polymorphisms
Pharmacogenomics
Cited by (0)
Financial Support: none.
The authors have no conflicts of interest to disclose.